HRT Insurance Appeal Letter Template: 6 Letters by Denial Type

Use this HRT insurance appeal letter template only after you copy the exact denial reason from your notice. Formulary, step-therapy, tiering, and quantity-limit disputes usually need a patient-specific prescriber statement; medical-necessity and benefit-category denials need a criterion-by-criterion appeal. Your plan type controls the form, deadline, and next level, so identify it before you send anything.

On this page, HRT means menopause hormone therapy for women. If you are appealing gender-affirming hormone therapy, thyroid replacement, testosterone therapy for men, a disability claim, or an urgent-care decision, this is not the right template set. Those disputes follow different clinical and administrative rules.

Best for you if: You have a written U.S. denial for a prescribed menopause medication—estrogen, progesterone, a combination product, or vaginal estrogen—and you want the letter, prescriber handoff, evidence list, and deadline in one place.

Not for you if: You only have a pharmacy error or backorder, you need urgent medical care, or you need legal interpretation of your specific plan contract. A template cannot do those jobs.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Which HRT insurance appeal letter template do you need?

Answer capsule: Start with the words printed on the denial—not the medication name and not the explanation you received by phone. The same estradiol patch can require a corrected claim, prior authorization, formulary exception, tiering exception, quantity-limit exception, internal appeal, or benefit-category correction. Pick the row that matches the written reason, then use the linked template.

The HRT Denial-to-Action Matrix

What the notice or claim says	What it usually means	First move	Who supplies the key information	When the decision clock starts	Template or route
Prior authorization required / missing information	The plan may not have made a final coverage decision yet	Ask the prescriber's office whether the PA was submitted, what is missing, and whether a denial was issued	Prescriber's office	Depends on the plan and whether a complete request was received	Finish or correct the PA before appealing
Invalid NDC / refill too soon / quantity entered incorrectly / pharmacy not in network	Claim-processing problem	Ask the pharmacist which field or rule rejected the claim and whether it can be corrected today	Pharmacy and prescriber's office	No appeal clock unless the plan issued a formal adverse decision	Correct and rerun the claim
Not on formulary / non-formulary	Formulary exception	Request the plan's exception form and criteria; attach a patient-specific prescriber statement	Prescriber	Plan-specific; for Medicare Part D exceptions, the standard clock normally starts when the plan receives the prescriber's supporting statement	Template 1
Must try another drug first / step therapy / fail first	Step-therapy exception or utilization-management exception	Identify the required alternative and the plan's exact exception test	Prescriber	Plan-specific; Part D treats this through its formulary-exception process	Template 2
Covered, but non-preferred tier / high copay	Tiering exception, if the plan offers one	Ask whether the drug is eligible for a tiering exception and what lower tier can be requested	Prescriber	Plan-specific	Template 3
Quantity limit exceeded	Quantity-limit or dose-restriction exception	Confirm the prescribed quantity and why the plan limit does not meet the documented regimen	Prescriber	Plan-specific; Part D uses its formulary-exception process	Template 4
Not medically necessary / criteria not met / clinical policy not met	Medical-judgment denial	Get the complete criterion and answer every element with chart evidence	You and prescriber	The date and route on the denial notice control	Template 5
Cosmetic / elective / wrong benefit category	Possible category or coding error	Ask which benefit category and plan provision were applied; correct the category with product and chart evidence	You and prescriber	The date and route on the denial notice control	Template 6
Not a covered benefit / benefit excluded	Contract or benefit-design denial	Request the exact plan or Summary Plan Description language and appeal its application if it is wrong	You, plan administrator, and sometimes prescriber	The date and route on the denial notice control	Use Template 5 as the frame, but argue plan language—not only medical necessity
Drug unavailable / backorder	Supply problem, not a coverage dispute	Ask the pharmacy which manufacturer, strength, package, and NDC are unavailable; call other pharmacies; speak with your prescriber before changing product or route	Pharmacy and prescriber	No appeal clock unless there is also a coverage denial	Do not send an appeal for inventory

Use the page in this order: copy the denial reason, identify the route in the matrix, then jump to the matching letter. Do not start by making the letter sound stronger. Start by making it the right request.

---

Is this a denial, a correction, an exception, or a supply problem?

Answer capsule: Not every pharmacy rejection is an appealable denial. An incomplete prior authorization, incorrect claim field, refill-too-soon edit, out-of-network pharmacy, or backorder may be fixed without an appeal. But a written decision denying coverage—including a decision that the benefit is excluded—can carry appeal rights. Get the written decision and its governing criterion before you write.

This section will probably talk some of you out of writing a letter at all. Good. Sending the wrong paperwork burns time you may not have.

1. The prior authorization was never completed

Your prescriber's office may have opened a PA and left a question unanswered, sent the wrong record, or never submitted it. If the plan has not made a decision, there may be nothing to appeal yet.

Call the office and ask:

“Was a prior authorization submitted for [drug], on what date, and what does the portal show right now—pending, incomplete, approved, or denied?”

If it is incomplete, ask what field or document is missing and when it will be sent. If it is denied, ask for the written denial and move to the matrix above.

2. The claim data are wrong

Wrong NDC. Wrong quantity. Wrong days' supply. Wrong refill date. Wrong pharmacy network. A claim can fail before anyone evaluates whether the medication should be covered.

Ask the pharmacist:

“What is the exact reject message and code, and can you tell me whether this is a claim-data problem, a coverage rule, or a formal denial?”

A corrected claim may be rerun immediately. An appeal letter cannot repair a field that was entered incorrectly.

3. The pharmacy cannot obtain the exact product

As of August 2026, the American Society of Health-System Pharmacists estradiol transdermal shortage bulletin shows a mixed NDC-by-NDC picture—not a blanket shortage of every estradiol patch. Some Dotti, Noven, Sandoz, Viatris, and Zydus packages or strengths are backordered, intermittent, or allocated while other listed products remain available.

Two pharmacies can give you two different answers because they use different wholesalers and stock different NDCs. If the pharmacy says “we can't get it,” ask which manufacturer, strength, package size, and NDC it tried to order.

An appeal cannot create inventory. The next move is another pharmacy or a conversation with your prescriber about a clinically appropriate manufacturer, strength, or route. Do not cut, split, substitute, or change a patch on your own.

→ We track the moving NDC-level details here: Estradiol Patch Shortage Tracker

4. The plan says the benefit itself is excluded

This one is different, but it is not automatically unappealable. HealthCare.gov lists a denial because a benefit is not offered under the plan among the decisions that can be taken through an internal appeal.

Medical evidence alone cannot rewrite a real exclusion. The first argument is whether the plan applied the right contract language to the right product and benefit.

Request all four:

1. 1. The exact plan, Evidence of Coverage, certificate, or Summary Plan Description provision relied on
2. 2. The definition of the excluded benefit or drug category
3. 3. The formulary or coverage policy in effect on the date of the request
4. 4. The appeal route and deadline for disputing the application of that language

Sometimes the exclusion is real. Sometimes a menopause prescription was pushed into the wrong category. You cannot know which fight you are in until you read the text.

The one honest thing most pages will not tell you

A template does not win an appeal. Evidence does.

The exact denial reason, the plan's own criterion, and what your prescriber can document matter more than how forcefully you write. Angry letters make noise. Precise letters make a record.

And there is a version of this where you should not spend six weeks fighting. For some generic estradiol and micronized progesterone prescriptions, the current local cash price may be lower than the copay you are trying to reduce. Check the exact product, strength, quantity, and pharmacy before you commit your evening to an appeal.

→ What HRT actually costs without insurance — current cash-pay routes and what to compare

The cash off-ramp is not only for generics. In November 2025, the FDA announced approval of the first generic version of Premarin (conjugated estrogens). That means the old claim that Premarin has no U.S. generic is no longer accurate. Approval does not guarantee that your pharmacy stocks the generic tablet or that your plan places it on a preferred tier, and it does not create a generic for every Premarin dosage form.

The moment cash pay stops being the answer is the moment this page becomes worth your evening: a product remains unaffordable, the tier is the problem, the plan refuses the prescribed route, or continuity matters enough that the exception is worth pursuing.

Get the written decision before you write anything

A point-of-sale pharmacy message may not contain the criterion, deadline, or appeal address you need. Request the plan's written decision—sometimes called an adverse benefit determination, coverage determination, denial notice, or Explanation of Benefits.

Call the number on your card and say:

“My prescription for [drug] was rejected on [date]. I need the exact reason and criterion in writing, whether the next step is a corrected claim, prior authorization, exception, or appeal, and the current form, deadline, and submission address, fax, or portal.”

Write down:

1. 1. Your name exactly as it appears on the policy
2. 2. Member ID
3. 3. Group number, if applicable
4. 4. Case, reference, or authorization number
5. 5. Date on the denial
6. 6. Denial reason word for word
7. 7. Drug name, strength, dosage form, quantity, and NDC if available
8. 8. Plan type: commercial/Marketplace, employer, Medicare Part D, Medicaid managed care, or Medicaid fee-for-service
9. 9. Representative's name, date and time of the call, and every submission instruction given

HealthCare.gov tells consumers to keep the denial, appeal request, supporting documents, authorization forms, and detailed call notes. That call log is worth more than it looks. If a deadline or missing document is disputed, it is your contemporaneous record.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

---

What does your prescriber need to prove?

Answer capsule: There is no universal federal “magic sentence” for every HRT denial. Medicare Part D has defined exception tests for formulary, step-therapy, tiering, and quantity-limit requests; commercial and Medicaid plans use their own forms and criteria. Your prescriber should answer the actual test, use patient-specific facts, and attach only documentation the chart supports.

This is the correction that matters most.

42 CFR 423.578 governs Medicare Part D exceptions. It does not turn one sentence into a universal rule for commercial insurance, employer plans, or Medicaid. It also says a prescriber's supporting statement does not produce an automatic favorable decision.

What the Part D rule does give you is a precise map of the findings the plan evaluates:

Denial type	Part D finding the prescriber addresses	What commercial or Medicaid readers should do
Non-formulary drug	Covered drugs for the same condition would be less effective for this enrollee, would cause adverse effects, or both; or the required alternatives meet the step-therapy or harm test	Use the plan's own exception form and quote its criterion; do not cite Part D as if it governs another plan
Step therapy	The required alternative was ineffective, or patient-specific clinical evidence supports that it is likely to be ineffective, impair effectiveness or adherence, cause an adverse reaction, or cause other harm	Name the required drug and document the actual prior result or the chart-supported reason it is inappropriate
Tiering	Preferred-tier drugs would be less effective, would cause adverse effects, or both	First confirm the plan allows a tiering exception and identify the eligible target tier
Quantity limit	The allowed number of doses was ineffective or is likely to be ineffective or impair effectiveness or adherence for this enrollee	State the prescribed quantity, days' supply, and patient-specific reason the plan limit does not meet the regimen
Medical necessity / criteria not met	No single Part D exception sentence replaces the plan's criteria	Get every criterion and answer it one by one with records
Benefit exclusion / wrong category	The Part D exception process cannot create coverage for a drug that is not a Part D drug	Argue the governing benefit language and category first; do not pretend a clinical sentence rewrites the contract

Three things that change what you do tonight

One: ask for the request by name. A drug can be covered yet unaffordable because it sits on a non-preferred tier. Ask whether the plan offers a tiering exception, not merely “help with my copay.” Under Part D, plans may exclude certain brand-to-generic tier moves and specialty-tier-to-non-specialty moves, so ask what target tier is actually available before filing.

Two: utilization-management rules can travel through one exception process. Under Part D, the formulary-exception process covers non-formulary drugs and coverage policies such as step therapy, prior authorization, and quantity limits. Your plan may present them on one form.

Three: “my doctor prescribed it” is not the full argument. It proves a prescription exists. It does not explain why the plan's covered alternative or limit fails the patient-specific test. The reviewer is looking for that bridge. Give them the bridge.

---

What are the six HRT insurance appeal letter templates?

Answer capsule: Use the letter matching the written denial, replace every bracketed field, and delete anything that is not true. Your cover letter can organize the request, but only the prescriber should make clinical findings. The suggested prescriber language below tracks Medicare Part D tests where identified; every other plan's current form and criterion remain controlling.

The packet has two voices:

• Your voice: identifiers, exact denial language, factual impact, requested remedy, attachments, and submission record
• Your prescriber's voice: diagnosis, relevant history, patient-specific clinical reasoning, prior trials or contraindications, and the response to the plan's criterion

Do not blur them. A patient signing a clinical conclusion does not make it clinician evidence.

Template 1: Formulary exception for a non-formulary drug

Use when the notice says: non-formulary, not on formulary, drug not covered, covered alternative required.

Do not use it blindly when the notice says “excluded.” “Excluded” can mean non-formulary, a true contract exclusion, or a non-Part-D drug. Ask which one.

[DATE]

[PLAN OR PBM NAME]
Pharmacy Coverage Determinations / Exceptions
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Request for formulary exception

Member: [NAME AS SHOWN ON POLICY]
Member ID: [NUMBER]
Group number: [NUMBER, IF APPLICABLE]
Case or reference number: [NUMBER]
Date of decision: [DATE]
Medication: [EXACT PRODUCT, STRENGTH, DOSAGE FORM, QUANTITY, AND NDC IF AVAILABLE]

To the review department:

I am requesting a formulary exception for [MEDICATION]. The written decision
issued on [DATE] states: “[COPY THE REASON EXACTLY].”

Please evaluate this request under the plan's current formulary-exception
criteria and include the enclosed patient-specific statement from my
prescribing clinician, [NAME, CREDENTIAL, NPI, PHONE, FAX].

PRESCRIBER SECTION — COMPLETE AND SIGN ONLY IF TRUE

The covered formulary alternative(s) for this patient's documented condition
would not be as effective as [MEDICATION], would cause adverse effects, or
both, for the following patient-specific reason(s):

[CLINICIAN DESCRIBES DOCUMENTED PRIOR RESULTS, ADVERSE EFFECTS,
CONTRAINDICATIONS, ROUTE NEED, EXCIPIENT ISSUE, OR OTHER RELEVANT FACTS.]

[FOR MEDICARE PART D: ADAPT THIS SECTION TO THE PLAN'S EXCEPTION FORM AND
42 CFR 423.578(b)(5). DO NOT PRESENT IT AS A GUARANTEE OF APPROVAL.]

Enclosures:
- Written denial or coverage determination
- Current plan criterion or exception form
- Signed prescriber statement
- [RELEVANT CHART NOTES]
- [DOCUMENTED TREATMENT OR FILL HISTORY]
- [CURRENT PRESCRIBING INFORMATION, ONLY IF IT ADDRESSES THE DISPUTE]

Please approve coverage of [MEDICATION] and send the decision in writing. If
this request is denied, please identify the plan provision, criterion, and
evidence relied on and provide the deadline and instructions for the next
level of review.

[NAME]
[PHONE]
[EMAIL]
[SIGNATURE]
[DATE]

Most common mistake: putting the prescriber's conclusion in your own signed statement. Give the clinician the criterion. Let the clinician decide what the record supports.

---

Template 2: Step-therapy exception

Use when the notice says: step therapy, fail first, preferred drug must be tried, prerequisite drug required.

[DATE]

[PLAN OR PBM NAME]
Pharmacy Coverage Determinations / Exceptions
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Request for step-therapy exception

Member: [NAME]
Member ID: [NUMBER]
Case or reference number: [NUMBER]
Date of decision: [DATE]
Requested medication: [PRODUCT, STRENGTH, DOSAGE FORM, QUANTITY]
Required alternative named by plan: [DRUG OR STEP]

To the review department:

I am requesting an exception to the step-therapy requirement applied to
[MEDICATION]. The written decision states: “[EXACT DENIAL LANGUAGE].”

Please apply the plan's current step-therapy exception criteria and review the
signed statement from my prescribing clinician.

PRESCRIBER SECTION — COMPLETE AND SIGN ONLY IF TRUE

[REQUIRED DRUG OR STEP] [WAS INEFFECTIVE / CAUSED THE DOCUMENTED ADVERSE
EFFECT / IS CLINICALLY INAPPROPRIATE FOR THIS PATIENT]. The patient-specific
basis is:

[DOCUMENTED DATES, RESPONSE, ADVERSE EFFECT, CONTRAINDICATION, INTERACTION,
EXCIPIENT ISSUE, ROUTE NEED, ADHERENCE ISSUE, OR OTHER SUPPORTED FACT.]

[FOR MEDICARE PART D: IF THE DRUG WAS NOT TRIED, EXPLAIN THE SOUND CLINICAL
EVIDENCE AND KNOWN PATIENT CHARACTERISTICS SUPPORTING WHY IT IS LIKELY TO BE
INEFFECTIVE, IMPAIR EFFECTIVENESS OR ADHERENCE, CAUSE AN ADVERSE REACTION, OR
CAUSE OTHER HARM. ADAPT TO THE PLAN FORM.]

Enclosures:
- Written decision
- Step-therapy policy and exception form
- Signed prescriber statement
- Relevant chart and fill history
- Other evidence directly answering the criterion

Please waive the step-therapy requirement and approve [MEDICATION]. If the
request is denied, please provide the complete rationale and next-review
instructions in writing.

[NAME]
[SIGNATURE]
[DATE]

Most common mistake: inventing a failed trial. If you never took the preferred drug, say that. A chart-supported reason it is inappropriate can be a legitimate exception basis. A fabricated fill history is not.

---

Template 3: Tiering exception

Use when: the medication is on the formulary but placed on a non-preferred or higher-cost tier.

[DATE]

[PLAN OR PBM NAME]
Pharmacy Coverage Determinations / Exceptions
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Request for tiering exception

Member: [NAME]
Member ID: [NUMBER]
Case or reference number: [NUMBER]
Medication: [PRODUCT, STRENGTH, DOSAGE FORM]
Current tier and cost sharing: [AS SHOWN BY PLAN]
Requested eligible tier: [CONFIRM WITH PLAN]

To the review department:

I am requesting a tiering exception for [MEDICATION]. The drug is listed on
[CURRENT TIER], and the plan advised that [PREFERRED DRUG(S)] are the
preferred-tier alternative(s).

PRESCRIBER SECTION — COMPLETE AND SIGN ONLY IF TRUE

The preferred-tier drug(s) for this patient's condition would not be as
effective as [MEDICATION], would cause adverse effects, or both, because:

[PATIENT-SPECIFIC CLINICAL REASON SUPPORTED BY THE CHART.]

[FOR MEDICARE PART D: ADAPT THIS TO THE PLAN'S TIERING-EXCEPTION FORM AND
42 CFR 423.578(a). CONFIRM THAT THE REQUESTED MOVE IS ELIGIBLE; CERTAIN
BRAND-TO-GENERIC AND SPECIALTY-TIER MOVES MAY BE EXCLUDED.]

Enclosures:
- Current formulary page showing the tier
- Current tiering-exception criteria or form
- Signed prescriber statement
- Relevant chart documentation

Please apply the lowest eligible preferred cost-sharing tier under the plan's
rules and send the decision in writing. If this drug is not eligible for a
tiering exception, please identify the exact rule and any other available
cost-sharing or coverage review.

[NAME]
[SIGNATURE]
[DATE]

Most common mistake: arguing that the copay is painful without addressing the preferred alternatives. Affordability explains why you filed. The exception test usually turns on clinical fit.

---

Template 4: Quantity-limit exception

Use when the notice says: quantity limit, plan maximum, dose limit, exceeds allowed units.

Check first: “Refill too soon” after a dose change may be a claim-edit problem. Ask whether a new prescription, corrected days' supply, or override can fix it before you appeal.

[DATE]

[PLAN OR PBM NAME]
Pharmacy Coverage Determinations / Exceptions
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Request for quantity-limit exception

Member: [NAME]
Member ID: [NUMBER]
Case or reference number: [NUMBER]
Medication: [PRODUCT, STRENGTH, DOSAGE FORM]
Prescribed quantity and days' supply: [AMOUNT]
Plan limit: [AMOUNT]

To the review department:

I am requesting an exception to the quantity or dose restriction applied to
[MEDICATION]. The written decision states: “[EXACT DENIAL LANGUAGE].”

PRESCRIBER SECTION — COMPLETE AND SIGN ONLY IF TRUE

The quantity permitted under the plan limit [WAS INEFFECTIVE / IS LIKELY TO
BE INEFFECTIVE / IS LIKELY TO IMPAIR THE EFFECTIVENESS OF TREATMENT OR
ADHERENCE] for this patient. The prescribed quantity is [AMOUNT] for a
[NUMBER]-day supply because:

[PATIENT-SPECIFIC, CHART-SUPPORTED CLINICAL REASON.]

[FOR MEDICARE PART D: ADAPT TO 42 CFR 423.578(b)(5)(iii) AND THE PLAN'S
CURRENT FORM.]

Enclosures:
- Written decision
- Quantity-limit criterion
- Current prescription
- Signed prescriber statement
- Relevant chart documentation

Please approve [PRESCRIBED QUANTITY] per [DAYS' SUPPLY] and send the decision
in writing. If denied, please provide the complete rationale and next-review
instructions.

[NAME]
[SIGNATURE]
[DATE]

Most common mistake: leaving the reviewer to reverse-engineer the math. Put the prescribed dose, units, application frequency, quantity, and days' supply in one place.

---

Template 5: Internal appeal for “not medically necessary”

Use when the notice says: not medically necessary, criteria not met, clinical policy not met, insufficient clinical information.

This is where your voice does real work. The plan applied written criteria. Your job is to force the file back onto those criteria, one at a time.

[DATE]

[PLAN NAME]
Appeals Department
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Internal appeal of medical-necessity determination

Member: [NAME]
Member ID: [NUMBER]
Group number: [NUMBER, IF APPLICABLE]
Case or reference number: [NUMBER]
Date of denial: [DATE]
Medication: [EXACT PRODUCT, STRENGTH, DOSAGE FORM, QUANTITY]

To the appeals department:

I am filing an internal appeal of the [DATE] decision denying coverage of
[MEDICATION]. The notice states: “[COPY THE REASON EXACTLY].”

I requested the complete clinical policy, criteria, and evidence used for the
determination. I am responding to each stated criterion below.

1. Plan criterion: [QUOTE THE FIRST CRITERION]
   Response: [VERIFIED FACT AND ENCLOSED DOCUMENT THAT ANSWERS IT]

2. Plan criterion: [QUOTE THE SECOND CRITERION]
   Response: [VERIFIED FACT AND ENCLOSED DOCUMENT THAT ANSWERS IT]

3. Plan criterion: [CONTINUE AS NEEDED]
   Response: [VERIFIED FACT AND ENCLOSED DOCUMENT]

Factual effect on daily functioning:
[SHORT, SPECIFIC DESCRIPTION—FOR EXAMPLE, DOCUMENTED NIGHT WAKINGS,
WORKDAYS AFFECTED, DURATION, OR WHAT CHANGED DURING A DOCUMENTED TREATMENT
PERIOD. DO NOT EXAGGERATE OR SUBSTITUTE THIS FOR THE CLINICAL CRITERIA.]

My prescribing clinician, [NAME, CREDENTIAL, NPI], has provided a signed
statement addressing the medical basis for this prescription and the plan's
criteria.

Enclosures:
- Denial notice
- Current clinical policy and criteria
- Signed prescriber statement
- Relevant chart notes
- Documented treatment and fill history
- Current prescribing information, when directly relevant
- Other evidence listed beside the criterion it answers

Please reverse the denial and approve [MEDICATION]. If the denial is upheld,
please identify every criterion not met, the plan provision and evidence
relied on, and the deadline and instructions for the next level of review,
including external review when applicable.

[NAME]
[PHONE]
[EMAIL]
[SIGNATURE]
[DATE]

Most common mistake: submitting a page of suffering and never answering the rule. Emotion is real. It is not a replacement for the criterion. One short factual impact paragraph, then straight back to the evidence.

---

Template 6: “Cosmetic,” “elective,” or wrong benefit category

Use when: the denial appears to classify diagnosed menopause care under the wrong category.

Use an FDA-approved indication only when the exact prescribed product has that indication in its current label. Do not use this paragraph to claim that a compounded preparation is FDA-approved. Do not turn an off-label prescription into an on-label one by changing the wording.

[DATE]

[PLAN NAME]
Appeals / Coverage Review Department
[ADDRESS, FAX, OR PORTAL FROM THE NOTICE]

RE: Request to correct benefit category and reconsider coverage

Member: [NAME]
Member ID: [NUMBER]
Case or reference number: [NUMBER]
Date of decision: [DATE]
Medication: [EXACT PRODUCT, STRENGTH, DOSAGE FORM]

To the review department:

I am appealing the [DATE] decision regarding [MEDICATION]. The notice states:
“[EXACT DENIAL LANGUAGE].”

The determination appears to categorize this request as [COSMETIC / ELECTIVE /
OTHER CATEGORY]. This prescription is for treatment of [DIAGNOSED CONDITION
AS DOCUMENTED BY PRESCRIBER], not for a cosmetic purpose.

[USE ONLY FOR THE EXACT FDA-APPROVED PRODUCT AND A CURRENT LABELED
INDICATION: The current FDA prescribing information for [PRODUCT] includes an
indication for [QUOTE OR ACCURATELY STATE THE INDICATION]. The relevant label
page is enclosed.]

Please identify the benefit category, code, plan definition, and provision
used. If the request was processed under the wrong category, please reprocess
it under the correct pharmacy or medical benefit and apply the relevant
coverage criteria.

My prescribing clinician's signed statement and relevant chart documentation
are enclosed.

If the plan maintains that the benefit is excluded, please provide the exact
contract, certificate, Evidence of Coverage, or Summary Plan Description text
and the appeal instructions for disputing its application.

[NAME]
[SIGNATURE]
[DATE]

Most common mistake: using a general article about hormone therapy instead of the current label for the exact prescribed product. The product, route, and indication have to match.

Copy the letter that matches your notice now. Replace every bracket, delete every unsupported sentence, and send the prescriber section with the plan's form and criterion—not by itself.

---

Who writes the appeal—you or your prescriber?

Answer capsule: You can usually organize and submit your own appeal or appoint a representative, but drug exceptions depend on clinical information from the prescriber. Medicare Part D permits oral or written supporting statements and may require written follow-up. The cleanest packet separates your administrative cover letter from the clinician's signed, patient-specific response to the plan's criterion.

This is where appeals stall. Not at the plan. At the handoff.

Task	You	Prescriber's office	Pharmacy	Plan or PBM
Save the written decision	Yes	May receive it	May see reject text	Issues it
Get exact pharmacy reject text	Ask	May ask	Supplies it	Can explain rule
Complete or correct a PA	Provide information	Leads	May rerun claim	Reviews complete request
State why alternatives or limits do not fit this patient	No clinical conclusion	Leads and signs	No	Applies criterion
Write cover letter and assemble packet	Leads	May help	No	Receives it
Supply policy, formulary, and criterion	Request	Request	May locate formulary	Supplies governing material under applicable rules
Submit through stated channel	You or representative	Often submits drug exception	Limited	Receives and timestamps
Keep proof and follow up	Leads	Keeps clinical record	Keeps claim record	Keeps case file

You can appoint a representative. For commercial external review, HealthCare.gov says a doctor or another medical professional who knows your condition can file on your behalf. Medicaid managed-care rules also allow an authorized representative, and the notice must explain the process.

Free help exists. HealthCare.gov says a state Consumer Assistance Program can help file an internal appeal. State Departments of Insurance can help with state-regulated plans. For a self-funded employer plan, process complaints may belong with the U.S. Department of Labor's Employee Benefits Security Administration.

---

What should your prescriber include—and leave out?

Answer capsule: The strongest prescriber statement names the exact product and route, quotes or answers the plan's criterion, and ties every conclusion to the patient's documented history. Useful facts include prior response, adverse effects, contraindications, excipient problems, adherence barriers, and why the requested route matters for this patient. Broad slogans about HRT weaken the file.

Before you assume your clinician is stonewalling you, look at the handoff. Many offices are buried. Every appeal you make easier is one that can move this week instead of living in a fax queue.

The verified menopause evidence library

Evidence that can be used	Exact scope	Best source
Current FDA-approved indication	Exact product, dosage form, and label only	FDA prescribing information and Drugs@FDA
Current Part D exception test	Part D only; use the plan form and patient-specific facts	42 CFR 423.578
Current professional menopause guidance	Use only for the disputed clinical point; it does not replace plan criteria	The Menopause Society position statements
Product-specific excipient issue	Only when the current label and patient record support it; brand Prometrium's current label lists peanut oil	Current DailyMed label
Patient-specific route rationale	The prescriber's documented judgment about this patient—not a claim that one route is best for everyone	Signed prescriber statement and chart
State mandate	Only if effective, applicable to the plan type, and relevant to the denied service	Enacted state law and regulator guidance

The FDA boxed-warning trap

We checked the FDA's live Menopausal Hormone Therapies with Updated Prescribing Information page on August 26, 2026. It lists six products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.

That does not make this sentence true for every prescription:

“The FDA removed the boxed warning from HRT.”

On February 12, 2026, the FDA announced approved labeling changes for those six named products, including removal of boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. The current label for the exact product still controls.

Generic estradiol patches, Estrace, Premarin, Climara, and Vivelle-Dot were not on the FDA's six-product live list when this page was verified. Do not write that a product's boxed warning changed unless its current label proves it.

The narrow version survives review:

“On February 12, 2026, the FDA announced approved labeling changes for six named menopausal hormone therapy products. [PRODUCT] is one of the listed products, and its current prescribing information is enclosed.”

Use it only when it is true and relevant.

Never put these claims in an appeal

Weak, false, or risky	Use instead
“My doctor prescribed it, so the plan has to cover it.”	Quote the criterion and attach the prescriber's patient-specific answer.
“Federal law requires every plan to approve this sentence.”	Identify the plan type and use the plan's actual rule; Part D expressly says a supporting statement is not an automatic approval.
“The FDA removed the boxed warning from all HRT.”	Name the exact product and verify its current label.
“This compounded product is FDA-approved, the same as, or equivalent to the approved version.”	State accurately that the finished compounded preparation is not FDA-approved; ask for the exact exclusion and discuss approved alternatives with the prescriber.
“This is natural and safer.”	Delete it. Use patient-specific, documented facts.
“Patches are safer than pills for everyone.”	Have the prescriber explain why the prescribed route fits this patient.
“I tried everything.”	List only documented products, dates, doses, outcomes, and reasons for stopping.
“My FSH proves I need HRT.”	Include a lab only if the plan's criterion asks for it and the clinician says it is relevant.
“The plan is discriminating against women.”	Use a discrimination argument only when you have a specific legal or factual basis. Otherwise answer the coverage criterion.

Keep testosterone language exact

Testosterone is a Schedule III controlled substance in the United States. It requires a lawful prescription, and ACOG states that there is currently no FDA-approved testosterone formulation for cisgender women. Do not minimize either fact in a menopause appeal. If a clinician prescribes testosterone off label, the appeal must accurately identify the product, indication, controlled-substance status, plan rule, and patient-specific rationale. This page's six templates are not a substitute for that separate analysis.

---

What should you attach to an HRT appeal?

Answer capsule: Send the smallest complete packet that answers the denial: the written decision, current plan criterion, signed prescriber statement, relevant chart evidence, documented treatment history, and proof of submission. Add the product label or clinical source only when it answers a disputed point. More pages do not make a stronger appeal; matched evidence does.

The attachment stack

Attachment	Include it when	What it proves	Common failure
Written denial or coverage determination	Always	Exact reason, date, case number, route, deadline	Sending a pharmacy receipt instead of the decision
Current exception or appeal form	Plan requires or provides one	Correct queue and required fields	Using an old form found elsewhere online
Current criterion or policy	Always for medical-necessity or utilization-management denials	The test being applied	Arguing before seeing the rule
Signed prescriber statement	Drug exception or medical-judgment dispute	Patient-specific clinical basis	Patient writes the conclusion and clinician never signs
Relevant chart notes	They directly answer a criterion	Documented history	Dumping the entire chart without marking the relevant pages
Pharmacy fill history	Prior trials or adherence are disputed	Drug, date, quantity, and fill pattern	Claiming a trial that does not appear in available records
Current prescribing information	Indication, dosage form, route, warning, or excipient is disputed	Exact FDA-approved product information	Attaching a label for a different product or dosage form
State-law excerpt	Law is effective and applies to this plan	Statutory coverage or refill rule	Quoting a pending bill or a law that does not bind the plan
Submission proof	Always	What was sent, when, and where	No fax confirmation, portal receipt, certified mail record, or screenshot
Call log	Always	Contemporaneous follow-up record	Keeping names and dates in memory only

The cover sheet that prevents orphaned pages

Put this on every fax or upload bundle:

APPEAL / EXCEPTION PACKET

Member: [NAME]
Member ID: [NUMBER]
Case or reference number: [NUMBER]
Medication: [PRODUCT, STRENGTH, DOSAGE FORM]
Request: [FORMULARY / STEP THERAPY / TIERING / QUANTITY / INTERNAL APPEAL]
Total pages including cover: [NUMBER]
Submitted: [DATE AND TIME]
Callback: [PHONE]

Documents enclosed:
1. [DENIAL]
2. [FORM]
3. [PRESCRIBER STATEMENT]
4. [CRITERION RESPONSE]
5. [OTHER]

Then verify receipt. “The fax went through” is not the same as “the case is complete.” Ask the plan to confirm the case number, page count, whether the prescriber statement is attached, and when the decision clock started.

---

How long do you have to appeal an HRT denial?

Answer capsule: The clock depends on the plan. Federal commercial-plan guidance uses 180 days for an internal appeal and four months for external review; Medicare Part D uses 65 days for a Level 1 redetermination; Medicaid managed care uses 60 days. Your notice controls the actual route and date. Copy its deadline before relying on any general table.

Three systems. Three clocks. Flattening them into one number is how appeal rights get lost.

Commercial, Marketplace, and many employer plans

The federal consumer process described by HealthCare.gov uses these timeframes:

Step	General federal timeframe	Source
Initial decision for prior authorization for treatment not yet received	15 days	HealthCare.gov
Initial decision for a claim involving care already received	30 days	HealthCare.gov
Initial urgent-care notice	72 hours	HealthCare.gov
File the internal appeal	Within 180 days of the denial notice	HealthCare.gov
Internal appeal involving treatment not yet received	30 days	HealthCare.gov
Internal appeal involving treatment already received	60 days	HealthCare.gov
Expedited internal appeal	As fast as the condition requires and at least within 4 business days	HealthCare.gov
Request external review	Within 4 months of the final denial	HealthCare.gov external review
Standard external review	No later than 45 days	HealthCare.gov
Expedited external review	No later than 72 hours, or sooner when medically urgent	HealthCare.gov
External-review charge	No charge under the HHS-administered federal process; no more than $25 under a contracted or state process	HealthCare.gov

The 72 hours and 4 business days are not interchangeable. HealthCare.gov uses 72 hours for an initial urgent-care decision and at least 4 business days for an expedited internal appeal. The denial notice and the rules governing your plan still control.

A live 2026 external-review extension

HealthCare.gov currently states that a person may qualify for an extension until October 2, 2026 when:

• the original external-review deadline fell between July 1 and August 3, 2026, and
• the plan uses the HHS-administered Federal External Review Process.

The page says this may affect people in Alabama, Florida, Georgia, Texas, Wisconsin, a U.S. territory other than Puerto Rico, or a state or local government plan in any state. Call the plan and ask whether it uses that process.

This callout expires October 2, 2026. Remove or reverify it after that date.

Medicare Part D

Step	Timeframe	Source
Standard coverage determination	72 hours	CMS coverage determinations
Expedited coverage determination	24 hours	CMS
Exception decision clock	Normally begins when the plan receives the prescriber's supporting statement	42 CFR 423.568
If no supporting statement arrives	After a 14-day waiting period, decision due within 72 hours for a standard request or 24 hours for an expedited request	42 CFR 423.568
Payment request for a drug already purchased	14 days	CMS
File Level 1 redetermination	Within 65 days of the initial denial notice	Medicare.gov
Standard redetermination—benefit	7 days	Medicare.gov
Standard redetermination—payment	14 days	Medicare.gov
Expedited redetermination	72 hours	Medicare.gov
File Level 2 reconsideration	Follow the redetermination notice; CMS currently states 65 days	CMS Part D reconsiderations

The Part D failure point: for an exception, mailing your cover letter does not necessarily start the standard 72-hour or expedited 24-hour decision clock. The prescriber's supporting statement normally does. Ask the plan to confirm when it received that statement and when the clock began.

Medicaid managed care

Step	Federal maximum or window	Source
File managed-care plan appeal	60 calendar days from the notice	42 CFR 438.402
Standard plan appeal decision	30 calendar days	42 CFR 438.408
Expedited plan appeal decision	72 hours	42 CFR 438.408
Permitted extension	Up to 14 calendar days under the rule's conditions	42 CFR 438.408
Request a State fair hearing after plan appeal	State-selected period no shorter than 90 days and no longer than 120 days from the plan's resolution notice	42 CFR 438.408
Ask to continue previously authorized benefits	File on time—within 10 calendar days after the plan sends the notice or before the intended effective date, whichever is later—and satisfy the other conditions	42 CFR 438.420

Medicaid fee-for-service hearing deadlines are state-specific within federal limits. Read the notice the day it arrives. The deadline to keep existing benefits in place can arrive far earlier than the ordinary appeal deadline.

---

Can you ask for a fast decision?

Answer capsule: Ask for expedited review when the standard timeline could seriously jeopardize life, health, or the ability to attain, maintain, or regain maximum function. The standard is clinical, not emotional. Ask your prescriber whether the facts meet it and to support the request. In an urgent commercial case, internal and external review may proceed at the same time.

Running low is stressful. Stress is not the test.

Ask your prescriber directly:

“Could the standard review timeline seriously jeopardize my health or my ability to attain, maintain, or regain maximum function? If so, will you support an expedited request and state why?”

If the clinician says yes, send that statement with the expedited request and ask the plan to confirm whether it accepted expedited handling. If it did not, ask for the written reason and the standard deadline.

HealthCare.gov says that in urgent situations a consumer may request external review at the same time as the internal appeal rather than waiting for the internal process to finish.

A safety line we will not soften: do not stop, start, split, ration, or substitute a prescribed hormone because of a coverage problem or because of anything on this page. If you face a treatment gap, contact your prescriber now.

---

How does Medicare Part D handle HRT exceptions and appeals?

Answer capsule: Part D uses its own vocabulary. An exception is a type of coverage determination, not yet an appeal. If the plan denies that request, Level 1 is a redetermination by the plan; Level 2 is reconsideration by the Independent Review Entity. Use the plan or CMS form, get the prescriber statement submitted, and track each level separately.

The vocabulary matters because the wrong request can reach the wrong queue.

The Part D ladder

1. 1. Coverage determination, including a formulary or tiering exception
2. 2. Redetermination by the Part D plan—Level 1 appeal
3. 3. Reconsideration by the Part D Independent Review Entity—Level 2
4. 4. Administrative Law Judge hearing, when the amount-in-controversy requirement is met
5. 5. Higher Medicare appeal levels

Medicare publishes model forms, and plans publish their own coverage-determination and redetermination forms. A letter can work, but the current form reduces the chance that a required identifier or authorization is missing.

Four Part D rules worth marking in the margin

1. The exception clock normally starts with the supporting statement. Confirm receipt. Do not assume the cover letter started it.

2. There is no automatic win. The regulation explicitly says that the prescriber's supporting statement does not mean the plan must decide favorably.

3. An exception can address more than a missing drug. CMS says a formulary exception can request coverage of a non-formulary Part D drug or waiver of a utilization-management rule such as prior authorization, step therapy, or quantity limit.

4. An approved exception normally lasts through the rest of the plan year. Continued coverage depends on remaining enrolled, continued prescribing, and the drug remaining safe for the condition. Recheck the new plan-year formulary instead of assuming the exception renewed.

What happens when the plan misses a deadline?

Do not simply restart the request. Ask the plan whether the case was forwarded to the next review level as required, get the answer in writing, and call Medicare or the plan's appeal unit if the file is stalled.

---

How does Medicaid handle an HRT denial?

Answer capsule: Read the adverse-benefit notice to determine whether the decision came from a Medicaid managed-care plan or the state fee-for-service program. Managed care generally requires the plan appeal first and uses a 60-day filing window. Fee-for-service hearing rules are state-specific. The notice also controls expedited handling, representation, case-file access, and continuation of existing benefits.

Do not guess from the logo on the card. A state card, managed-care card, pharmacy-benefit card, and plan administrator can all appear in the same wallet. The denial notice should identify the decision-maker and route.

Medicaid managed care

Federal rules require the notice to explain:

• the reason for the adverse benefit determination
• the right to appeal and how to do it
• the 60-day filing window
• the standard and expedited procedures
• the right to examine the case file and the medical-necessity criteria used
• how to request continuation of benefits when eligible
• how to request a State fair hearing after completing the plan appeal

An enrollee may file the managed-care appeal orally or in writing. Oral filing counts as the filing date. A provider or authorized representative may act for the enrollee under the plan's consent rules.

Medicaid fee-for-service

The State fair-hearing notice and deadline control. Federal regulation requires a reasonable time to request a hearing, not to exceed 90 days from the date the notice is mailed. Some states use a shorter window.

The deadline that matters when treatment is being stopped

If the plan is reducing, suspending, or terminating a previously authorized service, asking for continuation of benefits can have a separate early deadline. Under the managed-care rule, the appeal must be filed within 10 calendar days after the plan sends the notice or before the intended effective date, whichever is later, and the other regulatory conditions must be met.

That is not a detail to save for the weekend. Read the notice the day it arrives.

---

What if insurance denied compounded HRT?

Answer capsule: A compounded hormone denial follows a different path because the finished compounded drug is not FDA-approved and many plans exclude compounded prescriptions by benefit design. Get the exact exclusion and challenge its application only when it is wrong. Do not claim FDA approval or equivalence. Discuss covered FDA-approved options with your prescriber.

Compounded does not mean counterfeit. It does mean a different regulatory category.

The FDA says many products marketed as compounded “bioidentical hormones” are not FDA-approved, and it does not have evidence that they are safe and effective or safer or more effective than FDA-approved menopause hormone therapy. That does not decide what is clinically appropriate for one patient. It does decide what you can accurately claim in an insurance letter.

If the plan has a true compounded-drug exclusion

Get the exact language. Then ask:

• Does the exclusion apply to every compounded prescription or only certain pharmacy claims?
• Was the correct NDC or compound identifier submitted?
• Is the drug being denied under the pharmacy benefit, medical benefit, or both?
• Does the plan have a medical-necessity exception to the exclusion?
• Which FDA-approved products and routes are covered for the documented condition?

A true benefit exclusion may leave no clinical exception. Do not spend six pages pretending it is a formulary dispute.

What not to write

Do not write that the compounded product is FDA-approved, “the same as” an FDA-approved product, clinically proven equivalent, or safer because it is “natural.” Those claims blur categories the FDA treats separately and give the reviewer an easy reason to distrust the rest of the packet.

→ FDA-approved vs. compounded HRT: what actually differs

---

What happens if the internal appeal is denied?

Answer capsule: A final internal denial may qualify for independent external review when it involves medical judgment, an experimental or investigational determination, or rescission. The reviewer is outside the insurer, and the plan must accept the decision. The general filing window is four months. A pure contract exclusion may not qualify, so follow the final denial's exact external-review instructions.

This is a step many people skip, and it has real teeth.

HealthCare.gov says the external reviewer issues the final decision and the insurer is required by law to accept it. Standard review is due no later than 45 days; expedited review is due no later than 72 hours or sooner when medically urgent.

Denials that can go to external review under the federal consumer process

• medical-judgment denials where you or the provider disagree with the plan
• experimental or investigational determinations
• rescission of coverage based on alleged false or incomplete application information

A denial based only on a contract benefit exclusion is different. The final denial notice should identify whether external review is available and who handles it.

If the plan uses the HHS-administered process

The current HealthCare.gov page lists:

• secure online filing
• phone 1-888-866-6205 to request the form
• fax 1-888-866-6190
• email ferp@maximus.com
• mail to MAXIMUS Federal Services, 3750 Monroe Avenue, Suite 705, Pittsford, NY 14534

If the state runs the process or the plan contracts with an independent review organization, use the contact in the final denial rather than sending the packet to MAXIMUS.

Audit the final denial before you file

Check whether it:

1. 1. answers each criterion you addressed
2. 2. identifies the plan provision and evidence relied on
3. 3. explains the next level and deadline
4. 4. names the external-review organization when available
5. 5. includes the full case record or explains how to request it

Then send the external reviewer the final denial, original request, every prior submission, the criterion, and a short index showing where each disputed point is answered.

---

Does your state give you a menopause coverage law to quote?

Answer capsule: Several states now have enacted rules that can change an HRT appeal, but they do different jobs. Louisiana restricts prior authorization and step therapy; Illinois, New Jersey, and Oregon have menopause-coverage mandates; Washington requires a 12-month refill for already covered eligible hormone therapy. State rules usually do not bind self-funded ERISA plans, so verify plan funding first.

The stale version of this table said two states. That is no longer publishable.

State laws verified for this page on August 26, 2026

State	Effective status	What the enacted rule does	What it does not prove	Appeal use
Louisiana	R.S. 22:988, effective August 1, 2024	Requires coverage of medically necessary care and treatment for menopause and perimenopause and bars prior authorization, step therapy, and fail-first protocols for medication prescribed for HRT for menopause symptoms; the act also amended Medicaid provisions	It does not guarantee that every product, pharmacy, or compounded prescription is covered under every benefit	Quote the statute when an applicable Louisiana-regulated plan imposes the prohibited utilization rule
Illinois	Public Act 103-0703, effective January 1, 2026	Requires covered plans to cover medically necessary hormone therapy for menopause, no longer limiting the provision to hysterectomy-induced menopause; the law includes FDA-approved administration modalities named in the act	It does not make every requested product automatically medically necessary or bind every self-funded employer plan	Use the statute and exact route language when the denial conflicts with an applicable Illinois-regulated policy
New Jersey	P.L. 2025, c.200, approved January 9, 2026; most provisions effective April 9, 2026; the individual-plan section identified in the act starts January 1, 2027	Requires multiple regulated programs and plan types to cover medically necessary perimenopause and menopause treatment, including symptom treatment and specified service categories	The statutory use of “bioidentical” does not turn a compounded finished drug into an FDA-approved product or guarantee coverage of every formulation	Match the section to the plan type and effective date before quoting it
Oregon	HB 3064, effective January 1, 2026	Requires covered health benefit plans to cover a range of FDA-approved therapies for symptoms of perimenopause, menopause, and postmenopause	It is not a blanket ban on every utilization-management rule and does not cover non-FDA-approved finished compounded drugs as FDA-approved therapies	Use the enacted coverage requirement when an applicable Oregon-regulated plan denies a covered FDA-approved therapy
Washington	RCW 48.43.845 applies to plans issued or renewed on or after January 1, 2026	A plan that already covers prescription hormone therapy must reimburse a 12-month refill obtained at one time when the drug can be safely stored at room temperature; controlled substances receive the maximum allowed under state and federal law	It is not a general HRT coverage mandate, does not erase utilization management, and does not require 12 months of a refrigerated product	Use it for an eligible refill-quantity denial—not as proof that the plan must add a drug to its formulary

Primary state sources: Louisiana R.S. 22:988, Illinois Public Act 103-0703, New Jersey P.L. 2025, c.200, Oregon HB 3064, and Washington RCW 48.43.845.

The 30-second plan-funding test

State insurance mandates generally apply to state-regulated, fully insured coverage. A self-funded employer plan may carry a national insurer's logo while the employer pays the claims and the insurer only administers them.

KFF's 2025 Employer Health Benefits Survey reports that 67% of covered workers are in a self-funded plan, including 80% of covered workers at firms with 200 or more employees.

Before pasting a state statute into the appeal:

1. 1. Ask HR or the plan administrator: “Is this plan fully insured or self-funded?”
2. 2. Read the Summary Plan Description for the plan sponsor and funding language.
3. 3. Ask which regulator and appeal rules govern the plan.
4. 4. Quote the state law only after confirming it reaches your plan and was effective on the relevant date.

If the plan is self-funded, that does not erase federal claims and appeal rights. It changes which state mandates bind the benefit design.

---

How can you stay on treatment while the appeal is pending?

Answer capsule: Ask the prescriber and plan about a transition fill, bridge supply, corrected claim, covered alternative, or reimbursement route while the appeal moves. Paying cash does not automatically erase appeal rights, but reimbursement is not guaranteed outside the plan's rules. Save receipts and submit the claim exactly as instructed. Never change the dose, route, or product without the prescriber.

Three bridges, in the order to try them:

1. Ask whether a transition or temporary supply applies

Medicare Part D plans have transition requirements in defined circumstances, including certain plan-year and care-setting changes. Commercial transition policies are plan-specific. Ask:

“Does this plan have a transition-fill, continuity-of-care, emergency-supply, or temporary-override process for this drug?”

Get the quantity, pharmacy instructions, and effect on the pending exception in writing.

2. Keep the appeal alive if you pay cash

Save the itemized pharmacy receipt, prescription claim information, NDC, quantity, and date. Ask before paying whether the plan requires the pharmacy to submit the claim, whether you must file a member reimbursement form, and whether a later favorable decision can apply retroactively.

Under Part D, payment coverage determinations have a 14-day decision timeframe. Other plans use their own reimbursement rules. “Keep the receipt” is necessary. It is not a promise of repayment.

3. Discuss covered alternatives with the prescriber

If a covered FDA-approved product would work for you, using it can be a legitimate outcome—not surrender. The medication, route, and dose are clinical decisions. A website should not make them for you.

When the prescriber handoff is the bottleneck

A perfect template cannot make a clinician sign a statement the chart does not support. It also cannot make an overwhelmed office finish the form. Make the handoff smaller:

• attach the denial and plan criterion
• highlight the exact section the clinician must answer
• provide the pharmacy and treatment history you can verify
• put the deadline and submission channel on the first page
• ask the office to confirm submission, not merely completion

If the current clinician will not handle the appeal, a new clinician may be able to evaluate you and document a treatment plan. Do not assume that a telehealth visit includes appeal preparation. Confirm before booking.

Provider-stated vs. verified bridge options

Option	Provider-stated model	What we verified August 2026	Hard limit for this reader	Decision-resolution CTA
Midi Health	Menopause-focused virtual care that works with insurance and offers self-pay	Midi's current pricing and insurance page lists $250 for an initial self-pay visit and $150 for follow-ups and says it works with most major PPO plans nationwide. Its coverage guidance says it does not accept Medicaid or Medi-Cal and is not a participating Medicare provider; claims related to Midi visits, medications, or associated services cannot be submitted to Medicare.	Coverage, copay, network status, clinical appropriateness, and whether a clinician will handle an existing appeal must be confirmed before booking.	Check whether Midi works with your plan
Sesame	Direct-pay menopause membership and visits without billing insurance	Sesame's current menopause page displays the live subscription offer during booking and includes video care, messaging, and basic lab testing when clinically necessary; medication costs are separate. Public Sesame pages showed different promotional entry prices when checked, so we do not publish one fixed Sesame price here.	It does not solve an insurance-network problem. Prescribing remains clinician-controlled, lab availability varies in stated jurisdictions, and cancellation timing matters.	Compare cash-pay menopause care options
Existing in-network clinician	Continue established care and use the plan's own forms	No new intake relationship or affiliate cost	The office may not have capacity, and the record may still lack the facts the criterion requires	Send the denial, criterion, and one-page prescriber section today

Sesame cancellation terms: Its menopause page says cancel at least three hours before the initial visit for a full first-month refund; after that visit, the first month is nonrefundable. It says to cancel before the next billing cycle to avoid another charge. Sesame's Terms of Service state a stricter membership deadline of up to 48 hours before renewal and no prorated refund. Use the stricter 48-hour rule and recheck the terms shown at checkout before paying.

Affiliate disclosure: The Midi link is an affiliate link. The HRT Index may earn a commission if you book. That does not change the Medicaid, Medicare, pricing, or documentation limits above.

Why this page does not send an insurance appeal to a compounded-first provider

Winona offers both FDA-approved and compounded prescription options. Inner Balance's Oestra is marketed as compounded. A compounded finished drug is not FDA-approved, and insurance coverage for compounded prescriptions often turns on a separate exclusion.

That makes a compounded-first route the wrong default on a page whose job is to win or correctly route an insurance coverage dispute. If you decide to leave the insurance route and compare cash-pay care, that is a different decision with a different provider set.

→ Best online HRT providers for menopause

---

What did The HRT Index verify for this page?

Answer capsule: We verified the federal commercial, Medicare Part D, and Medicaid appeal rules; live FDA labeling and compounding statements; current state statutes; estradiol-patch shortage details; self-funded-plan prevalence; and provider pricing and coverage policies. We did not invent an HRT appeal success rate, claim clinical or legal review, promise a tool that does not exist, or publish fabricated testimonials.

Opened and checked on August 26, 2026

• HealthCare.gov internal appeal and external review pages, including the live October 2, 2026 extension, costs, deadlines, and authorized-representative language
• 42 CFR 423.568 and 423.578, plus CMS Part D coverage-determination, exception, redetermination, and reconsideration guidance
• 42 CFR Part 438 Subpart F and 42 CFR 431.221 for Medicaid appeal, hearing, and benefit-continuation rules
• FDA's live six-product labeling page and February 12, 2026 labeling-change announcement
• FDA's November 2025 Premarin generic announcement and current generic-program material
• FDA's menopause page separating FDA-approved from compounded hormone therapy
• Current product labeling used for the Prometrium excipient example
• ASHP's estradiol transdermal shortage bulletin
• Louisiana R.S. 22:988, Illinois Public Act 103-0703, New Jersey P.L. 2025 c.200, Oregon HB 3064, and Washington RCW 48.43.845
• KFF's 2025 Employer Health Benefits Survey
• Midi's pricing, insurance, Medicare, and Medicaid pages; Sesame's current menopause-treatment page

What we did not do—and will not pretend we did

• We did not publish an HRT appeal success rate. There is no verified national menopause-drug appeal success rate that can honestly be placed above the fold.
• We did not publish testimonials. We do not have permissioned, attributable statements from women who used these templates.
• We did not claim this page was reviewed by a clinician or attorney. It was not.
• We did not claim that one federal sentence binds every plan. It does not.
• We did not treat a pending bill as law. The state table contains enacted rules and effective dates.
• We did not promise a browser builder, Word download, PDF download, deadline calculator, calendar file, or local-only privacy architecture that has not been shipped and audited. The live page itself contains the complete templates.
• We did not turn provider marketing into an appeal-service promise. A clinician must independently evaluate the patient and decide what documentation is appropriate.

How this page was checked: provider and policy claims were reviewed under The HRT Index Verification Standard across clinical legitimacy, care quality, medication fit, price transparency, and access. No numeric provider score was created.

---

Frequently asked questions

Answer capsule: These answers close the practical follow-ups most readers face after choosing a template: who may file, which deadlines apply, what the prescriber must submit, how cash payment and backorders affect the case, how compounded products and testosterone differ, and when plan funding changes the rule. Your own denial notice remains the controlling instruction.

Can I write an HRT insurance appeal letter myself?

Yes. You can organize and submit the cover letter, evidence index, and administrative record. A formulary, step-therapy, tiering, quantity-limit, or medical-necessity dispute still needs the clinical information the plan requests. Only your prescriber should sign a patient-specific clinical conclusion.

Does my doctor have to send the appeal?

Not always. You or an authorized representative may be able to submit it. The plan may require the prescriber's statement or form to come directly from the office, especially for a drug exception. Ask which document must come from whom and confirm receipt of each piece.

What is the difference between an exception and an appeal?

An exception asks the plan to depart from its normal formulary, tier, step-therapy, prior-authorization, or quantity rule. An appeal asks the plan or next reviewer to reconsider a decision already made. Under Medicare Part D, an exception is a type of coverage determination; redetermination is the Level 1 appeal after denial.

How long do I have to appeal an HRT denial?

The common federal windows are 180 days for a commercial internal appeal, 65 days for a Medicare Part D redetermination, and 60 days for a Medicaid managed-care appeal. External review commonly uses four months after the final denial. Your own notice controls the exact route and deadline.

What if my doctor will not write the supporting statement?

Send the office the exact denial, the plan's criterion or exception form, the deadline, and the one-page prescriber section. Ask whether the record supports the request and whether the office will submit it. If not, ask what is missing. A new clinician can evaluate you, but no legitimate clinician should sign a conclusion without an independent basis.

Does appealing cost money?

The internal appeal itself should not carry a filing charge. Under the HealthCare.gov external-review process, the HHS-administered federal route is free; a contracted independent review organization or state process may charge no more than $25. Your ordinary costs for records, postage, visits, medication, or legal help are separate.

Should I appeal by phone or in writing?

Use the phone to identify the route, criterion, deadline, and case number. Use the plan's written, fax, or portal process to create a dated submission record. Medicaid managed-care appeals may be filed orally under federal rules, but save the date, time, representative, and confirmation number and follow every instruction in the notice.

My pharmacy says the medication is on backorder. Can I appeal that?

Not as a supply problem. An appeal cannot produce inventory. Ask which NDC is unavailable, call other pharmacies, and speak with your prescriber about a clinically appropriate alternative before changing anything. If the plan separately refuses to cover an available alternative, that coverage decision may be appealable.

Can I appeal a denial for compounded hormones?

You can use the route in the notice, but the argument is different. Get the exact compounded-drug exclusion and ask whether it was applied correctly. Do not claim that the finished compounded preparation is FDA-approved or equivalent to an FDA-approved product. Discuss covered FDA-approved options with your prescriber.

Will paying cash hurt my appeal?

Paying cash does not automatically waive appeal rights. Reimbursement is not automatic either. Before paying, ask whether the claim must be submitted at the pharmacy, whether a member reimbursement form is required, and whether a favorable decision can apply retroactively. Keep the itemized receipt and NDC.

Can I appeal a patch denial if the plan covers a pill?

Yes, when the plan has issued an appealable coverage decision. The exact route may be a formulary, step-therapy, medical-necessity, or benefit-category dispute. The prescriber should explain the patient-specific reason for the prescribed route and answer the plan's criterion without claiming that patches are best for everyone.

How do I know whether my employer plan is self-funded?

Ask HR or the plan administrator directly: “Is this health plan fully insured or self-funded?” Then check the Summary Plan Description. The insurer logo alone does not answer the question. State coverage mandates generally do not bind self-funded ERISA plans in the same way.

What if I never received a written denial?

Call the plan and request the decision, exact reason, criterion, case number, deadline, current form, and submission instructions in writing. A point-of-sale pharmacy message is usually not enough to build the right packet.

Is testosterone handled the same way?

No. Testosterone is a Schedule III controlled substance, requires a lawful prescription, and no FDA-approved testosterone formulation currently exists for cisgender women. An appeal involving off-label testosterone needs product-specific, controlled-substance, plan, and clinical analysis beyond a generic menopause-drug template.

Is this medical or legal advice?

No. This page explains public appeal processes and supplies editable drafting language. It cannot decide whether a medication is right for you, interpret your plan as an attorney would, or predict an outcome.

---

What is the bottom line?

Answer capsule: A denial notice is a routing document, not a verdict. Copy the exact reason. Identify the plan and remedy. Get the criterion. Separate your cover letter from the prescriber's clinical statement. Attach matched evidence. Submit through the stated channel, keep proof, track the deadline, and use the next review level instead of sending a louder version of the wrong request.

That is the whole procedure.

Not a magic sentence. Not a threat. Not a ten-page autobiography.

The right request. The right evidence. The right clock.

You are perfectly capable of running it.

Start with the HRT Denial-to-Action Matrix above, then copy the matching letter. If the real decision is no longer “how do I appeal?” but “which care path fits me now?”, use Find My HRT Path before booking another consult.

---

The HRT Index provides educational editorial research for women comparing menopause and HRT care. This page is not medical or legal advice and has not been medically reviewed by a clinician. The labeled Midi link is an affiliate link; The HRT Index may earn a commission if a reader books through it. Last verified August 2026.